Impact of demographic and psychosocial factors on adherence to antiretroviral treatment;Impacto de los factores demográficos y psicosociales en la no adherencia a los fármacos antirretrovirales

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 6, 2006, Pages 373-378

  Ruiz Pérez, Isabel ^a   De Labry Lima, Antonio Olry ^a   Prada Pardal, José L ^b   Rodríguez Baño, Jesús ^c   Causse Prados, Manuel ^d   López Ruz, Miguel A ^e   Martín Rico, Patricia ^d   Del Arco Jiménez, Alfonso ^b   Pasquau Liaño, Juan ^e   De La Torre Lima, Javier ^b   López Gómez, Manuel ^e   Muñoz Roca, Nuria ^e   Marcos Herrero, Miguel ^d   Muñoz, Isabel ^e   Morales Rojas, Dolores ^c  

^a ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^b HOSPITAL COSTA DEL SOL   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Adherence; Antiretroviral; Psychological factors

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BACTERIUM ADHERENCE; BISEXUALITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEALTH CARE PERSONNEL; HEPATITIS C; HOMOSEXUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MORBIDITY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM; SOCIAL PSYCHOLOGY;

EID: 33746495000     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13089691     Document Type: Article

References (20)

1. Anastos K, Barrón Y, Cohen M, Greenblatt R, Minkoff H, Levine A, et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med. 2004;140:256-64.
2. Kleeberger CA, Buechner J, Palella F, Detels R, Riddler S, Godfrey R, et al. Changes in adherence to Highly Active Antiretroviral therapy medications in the Multicenter AIDS cohort study. AIDS. 2004;18:683-8.
3. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reported. Patient Educ Couns. 2002;46:91-2.
4. Knobel H, Escobar I, Polo R, Ortega L, Martín-Conde T, Casado JL, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretroviral en el año 2004. Enferm Infecc Microbiol Clin. 2005;23:221-31.
5. Adherence to long-term therapies: evidence for action. En Human immunodeficiency virus and acquired immunodeficiency syndrome. Genève: World Health Organization; 2003. p. 95-106.
6. Puigventós F, Riera M, Delibes C, Peñaranda M, De la Fuente L, Boronat A. Estudios de adherencia a los fármacos antiretrovirales. Una revisión sistematica. Med Clin (Barc). 2002;119:130-7.
7. Ancelle-Park R. Expanded European AIDS case definition [letter]. Lancet. 1993;341:441.
8. Bellón JA, Delgado A, De Dios J, Lardelli P. Validez y fiabilidad del cuestionario de Apoyo Social funcional de Duke-UNC-11. Aten Primaria. 1996;18:153-63.
9. Lobo A, Pérez-Echevarría MJ, Artal J. Validity of the scaled version of the General Health Questionnaire (GHQ-28) in a Spanish populations. Psychol Med. 1986;16:135-40.
10. Badia X, Podzamczer D, López-Lavid C, Garcia M. Medicina basada en la evidencia y la validación de cuestionarios de calidad de vida; La versión española del MOS-HIV para la evaluación de la calidad de vida en pacientes infectados por el VIH. Enferm Infecc Microbiol Clin. 1999;17 Supl 2:103-13.
11. Haubrich RH, Little SJ, Currier JS, Forthal D, Kemper C, Beall GN, et al. The value of patient-reported adherence to antirretroviral therapy in predicting virologic and immunologic response. AIDS. 1999;13:1099-107.
12. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, et al. Patient-Reported nonadherence to HAART is related to Protease inhibitor levels. J Acquir Immune Defic Syndr Hum Retrovirol. 2000;24:123-8.
13. Tuldrá A, Ferrer JM, Fumaz CR, Bayes R, Paredes R, Burger DM, et al. Monitoring adherence to HIV therapy. Arch Intern Med. 1999;159:1376-7.
14. Garber M, Nau D, Erickson S, Aikens J, Lawrence J. The concordance of selfreport with other measures of medication adherence. Med Care. 2004;42:649-52.
15. DiMatteo, Lepper H, Crogham T. Depression is a risk factor for noncompliance with medical treatment. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-7.
16. Cruess DG, Petitto JM, Leserman J, Douglas SD, Gettes DR, Ten Have TR, et al. Depression and HIV Infection: Impact on Immune Function and Disease Progression. CNS Spectrums. 2003;8:52-8.
17. Evans D, Have T, Douglas S, Gettes D, Morrison M, Chiappini M, et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry. 2002;159:1752-9.
18. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
19. Wutoh A, Elekwachi O, Clarke-Tasker V, Daftary M, Powell N, Campuzano G. Assessment and predictors of antiretroviral adherence in older HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:S106-S14.
20. Hinkin C, Ardí D, Mason K, Castellón S, Durvasula R, Lam M, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18 Suppl 1:19-25.